Mechanism of Action:

​

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors to improve insulin secretion, reduce glucagon levels, enhance satiety, and increase energy expenditure. This coordinated receptor engagement supports improved glycemic control, appetite regulation, and lipid metabolism

​

Clinical Relevance & Potential Outcomes:

​

Clinical and preclinical studies suggest that Retatrutide may promote significant improvements in body weight, glycemic control, and metabolic biomarkers, including insulin sensitivity and adiposity reduction. It represents a promising approach for multi-pathway metabolic optimization.

​

Intended Clinical Application:

​

Retatrutide may be relevant for patients requiring comprehensive metabolic support, weight management, or enhanced glycemic regulation, particularly in cases of obesity, insulin resistance, or type 2 diabetes.